Hopstem Biotechnology

Executive Summary

Hopstem Biotechnology is a clinical-stage company developing induced pluripotent stem cell (iPSC)-derived cell therapies for severe neurological diseases, with a lead program targeting chronic ischemic stroke sequelae. Founded in 2016 and headquartered in San Diego with R&D and manufacturing in Hangzhou, China, the company leverages iPSC technology to create scalable, allogeneic cell therapies. Its pipeline is focused on addressing the high unmet need in stroke recovery, where current treatments are limited. By differentiating into neuronal lineages, Hopstem's therapy aims to restore neural function and improve patient outcomes. The company has not disclosed specific funding or valuation, but its dual presence in the US and China may enable access to diverse capital and regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead program in chronic ischemic stroke60% success
• Q4 2026Orphan Drug Designation from FDA for stroke sequelae50% success
• Q1 2027Strategic partnership for manufacturing or commercialization40% success